The BIOSECURE Act bars US federal agencies, and the companies that work for them, from using biotech equipment or services supplied by “biotechnology companies of concern.” The law names no companies. The Office of Management and Budget (OMB) must publish the first list by December 18, 2026, and that list will decide how much drug development and manufacturing work leaves Chinese CDMOs.
BIOSECURE Act: latest updates
- Nov 10, 2026: The Department of War removed WuXi AppTec from its Section 1260H list of Chinese military companies to comply with a court injunction, without prejudice to relisting.
- Oct 22, 2026: Treasury proposed a rule that would prohibit covered US investments in Chinese biotech, including in any company on the 1260H or BIOSECURE lists. Comments are due December 7.
- Aug 7, 2026: A federal court in Washington, DC blocked WuXi AppTec’s 1260H designation, finding the department misread its own evidence on state and military ties.
- Jun 8, 2026: The annual 1260H update added about 65 entities, including WuXi AppTec, Complete Genomics and Novogene.
BIOSECURE Act at a glance
| Region | United States |
| Instrument | Section 851, National Defense Authorization Act for Fiscal Year 2026 |
| Enacted | December 18, 2025 |
| Who it binds | Federal agencies, federal contractors, and recipients of federal grants and loans |
| Designation routes | Pentagon 1260H list plus an OMB finding, or a direct OMB finding |
| Legal status | In force; prohibitions not yet applying |
| Key date | OMB list of biotechnology companies of concern due December 18, 2026 |
| Grandfathering | Contracts signed before a designation run for five years after the contract rule takes effect |
| Most exposed | Sponsors with federal contracts, grants or VA supply schedule products made with Chinese CRO or CDMO support |
| Official source | Congress.gov |
| PharmaSource Score | 432 (rank 3) Impact 9, Reach 6, Likelihood 8 Download the PharmaSource Regulatory Radar |
What the BIOSECURE Act is
BIOSECURE spent two years as a standalone bill that named five Chinese companies: BGI, MGI, Complete Genomics, WuXi AppTec and WuXi Biologics. It stalled in 2024. Congress revived it inside the 2026 defense bill as Section 851, swapped the names for a listing process, and the President signed it on December 18, 2025.
The law works through seven levers:
- Three bans: Agencies may not buy biotech equipment or services from a company of concern, contract with anyone who uses them to perform federal work, or fund their use through grants or loans.
- Two routes onto the list: Route one takes a company on the Pentagon’s 1260H list and adds an OMB finding that it works in biotech. Route two lets OMB designate any biotech company controlled by or acting for a foreign adversary government that poses a national security risk, with no reference to 1260H.
- Annual review: OMB must update the list at least once a year.
- Staged start: OMB issues guidance within 180 days of the list, then the FAR Council writes contract rules within a year of the guidance.
- Grandfathering: Contracts signed before a company is designated continue for five years after the contract rule. Companies already on 1260H at enactment, such as BGI and MGI, get no grandfathering.
- Waivers: Up to 365 days with OMB approval and notice to Congress, plus one 180-day extension.
- Medicaid safeguard: Medicare Part B and Medicaid eligibility are preserved, though products sold through the VA Federal Supply Schedule stay exposed.
Where the BIOSECURE Act stands
- December 18, 2025: Signed into law. The same day, committee chairs in both chambers urged the Pentagon to add WuXi AppTec, WuXi Biologics and WuXi XDC to 1260H.
- June 8, 2026: The 1260H update adds WuXi AppTec, backed by a single-sentence justification citing indirect state ownership. WuXi sues three days later.
- June 30, 2026: A separate law, Section 805 of the 2024 defense act, bars the Pentagon from contracting directly with 1260H-listed companies.
- August 7, 2026: The court grants WuXi a preliminary injunction.
- November 10, 2026: The Federal Register publishes WuXi AppTec’s removal from 1260H.
- December 18, 2026: OMB’s first list is due.
The 1260H list has been an unsteady foundation. Before the June update, a revised list appeared in the Federal Register and was pulled; Gil Roth, President of the Pharma & Biopharma Outsourcing Association, told the PharmaSource Podcast it was withdrawn “within 15 to 20 minutes.”
The court ruling closes only route one. OMB is not a party to the case and can still name WuXi AppTec through route two. WuXi Biologics has never been on 1260H, and Ropes & Gray reads route one as unable to reach it, so its fate also rests on OMB’s direct finding.
What the BIOSECURE Act means for manufacturing and outsourcing
The law covers only federal work, but its commercial pull runs much wider. After WuXi AppTec’s June listing, customers cancelled contracts and moved programs to competitors within weeks, the court found. Demand for Chinese capacity has held up all the same: WuXi AppTec took 77% of its first-half 2026 revenue from US customers, and about half of WuXi Biologics’ 209 new projects in 2025 came from US clients. The exposure differs by company:
- Sponsors with federal exposure: Companies with government contracts, BARDA or NIH funding, or VA supply schedule products face the bans directly. Holland & Knight estimates that switching suppliers takes two to eight years for marketed-product manufacturing.
- Sponsors without federal exposure: These companies have no legal duty, but acquirers, partners and investors with federal work will ask. Public biotechs now list BIOSECURE as a risk factor in their SEC filings.
- Chinese CROs and CDMOs: The OMB list decides their US prospects. A company left off keeps its pricing and speed advantage; a company named starts a five-year wind-down of federal-linked work.
- CDMOs in Korea, India, Europe and the US: These companies win the programs that move. Samsung Biologics bought a US plant in Rockville after BIOSECURE passed, and Seoul’s CDMO Special Act aims to pull more work outside China.
- Biotechs in-licensing Chinese assets: Treasury’s proposed outbound rule and pending licensing bills add a second layer of review on top of BIOSECURE.
Former Gilead SVP Reza Oliyai told the PharmaSource Podcast that “intrinsically, there is nothing wrong with using Chinese CDMOs,” and advised sponsors to avoid knee-jerk reactions. For outsourcing leaders, the practical step is to map every China touchpoint by program, add designation-triggered termination and tech-transfer cost clauses to CDMO contracts, and start qualifying a second site for commercial products with federal exposure.
Why supporters back the BIOSECURE Act
“BGI, WuXi AppTec, and Wuxi Biologics all pose unacceptable threats to national security.”
John Moolenaar, Chair, House Select Committee on the CCP, in floor remarks in September 2024
- Data and know-how: Supporters argue that companies tied to a foreign adversary government could be made to hand over US genetic data and intellectual property.
- Supply chain concentration: A large share of US drug discovery and early manufacturing runs through a few Chinese providers, which supporters see as a strategic weakness.
- A process in place of names: The listing mechanism, with annual review and an appeal route, gives companies a way to contest designation that the 2024 bill lacked.
- A long runway: Staged rules and five-year grandfathering give sponsors years to move programs before any ban bites.
- Investment at home: The same defense act funds new Pentagon biotech programs, which supporters see as the other half of decoupling.
Criticisms of the BIOSECURE Act
“A scarlet letter sends a clear message: keep away.”
US District Court for the District of Columbia, ruling on WuXi AppTec’s 1260H designation, via Holland & Knight
- Thin evidence: The court found that a “5.32% stake” the Pentagon cited was a state fund’s portfolio allocation; its actual holding in WuXi AppTec was closer to 0.001%.
- Harm before any ban: Customers left WuXi within weeks of a listing that carried no BIOSECURE prohibition yet, so a designation punishes before it is tested.
- Cost for small biotechs: Tech transfers out of high-quality Chinese sites take years and money that small biotechs lack. Outsourced Pharma’s Louis Garguilo has argued against the WuXi listing in more than a dozen editorials since 2024.
- Overlapping regimes: Section 805, Treasury’s outbound rules, export controls and pending licensing bills each draw their own lines, so compliance teams track several lists at once.
- Uncertainty: Four weeks before the deadline, sponsors still do not know which companies OMB will name.
What’s next for the BIOSECURE Act
- December 18, 2026: OMB publishes its first list. Watch for WuXi AppTec, WuXi Biologics and WuXi XDC.
- Mid-2027: OMB guidance is due within 180 days of the list. On June 30, 2027, Section 805 extends to Pentagon contracts that use a listed company anywhere in the supply chain.
- 2028: The FAR rule follows by about June 2028, and the bans attach 60 to 90 days later, roughly August to September 2028. Grandfathered contracts run to about 2033.
- WuXi litigation: The merits case continues, and the Pentagon can relist WuXi AppTec on new grounds.
- Our score: Impact 9, Reach 6, Likelihood 8, giving 432 and rank 3. The December list will move this score more than anything else; if it leaves out the WuXi companies, Impact falls.
Related articles
- Korea’s CDMO Special Act: How Seoul Is Building a Biologics Hub Outside China (Nov 19, 2026)
- FDA Foreign Inspections and PreCheck: Tougher Scrutiny Abroad, a Fast Lane at Home (Nov 19, 2026)
- “Europe Needs to Pick a Side”: Why Geopolitics Is Forcing a Rethink of Pharma Supply Network Design (Sep 24, 2026)
- Tariffs, FDA Chaos, and BioSecure in Limbo: How CDMOs Should Operate Under Uncertainty (Jun 28, 2026)
- All coverage: Biosecure